Inpatient Management of Diabetes Mellitus - PowerPoint PPT Presentation

About This Presentation
Title:

Inpatient Management of Diabetes Mellitus

Description:

Inpatient Management of Diabetes Mellitus William Harper, MD, FRCPC Endocrinology & Metabolism Assistant Professor of Medicine, McMaster University – PowerPoint PPT presentation

Number of Views:169
Avg rating:3.0/5.0
Slides: 37
Provided by: Wilia
Category:

less

Transcript and Presenter's Notes

Title: Inpatient Management of Diabetes Mellitus


1
Inpatient Management of Diabetes Mellitus
  • William Harper, MD, FRCPC
  • Endocrinology Metabolism
  • Assistant Professor of Medicine, McMaster
    University

2
DKA
  • Monitored setting if Hi-risk
  • elderly CAD, pH lt 7.0, severe K disturbance,
    decreased LOC
  • IV Fluid Resuscitation (6-8L deficit)
  • Potassium (no pee no K)
  • IV insulin
  • Identify Rx underlying cause
  • Noncompliance, infection, MI, etc.

3
DKA IV Fluids
  • IV NS 1L/h x 2-3h or longer so no more
    tachycardia, hypotension, orthostatic changes,
    low JVP.
  • Then change to 1/2 NS
  • 500 cc/h x 1-3h
  • 250 cc/h x 4-6h
  • If hypotension recalcitrant to fluids consider AI
    (Schmidt PGAS II) and send stat cortisol then
    give solucortef 100 mg IV q8h.

4
DKA Mortality
  • Adults 2-4
  • Hypokalemia
  • MI, CVA, etc.
  • Kids 0.2-0.4
  • Cerebral edema

5
DKA Potassium
  • Need K with initial IV fluid insulin Rx unless
  • Anuric
  • K gt 5.5 mEq/L or hyperkalemic ECG changes

Initial K Replacement
gt 5.5 mEq/L nil (initially)
5.2-5.5 mEq/L 10 mEq/h
4-5.2 mEq/L 20 mEq/h
3-4 mEq/L 30 mEq/h
lt 3 mEq/L 40 mEq/h
gt 20 mEq/h Cardiac monitor gt 60 mEq/L Central
line
6
DKA IV Insulin
  • Humulin R or Novolin Toronto
  • Bolus 0.1-0.2 U/kg IV
  • Then IV gtt _at_ 0.1-0.2 U/kg/h
  • (50 U of regular insulin in 500cc D5W
    1U/10cc)
  • Monitor CBG q1h
  • Monitor Venous BS, electrolytes, creatinine q2h
  • Aim is to demonstrate correction of Anion Gap
    (AG) and decrease in BS 4.4 mM/L/h
  • Monitoring serial serum ketones NOT useful
  • ßHß (not detected) DKA Rx Acetoacetate
    (detected)

7
DKA IV Insulin
  • Using insulin to treat 2 different and separate
    metabolic disturbances in DKA
  • Ketoacidosis
  • Hyperglycemia

8
DKA IV Insulin
  • If AG not correcting and/or BS not decreasing
    then increase IV gtt rate 1.5-2X
  • If BS lt 13 but AG still not corrected do NOT
    decrease insulin IV gtt.
  • Instead start IV glucose gtt
  • D5W-D10W _at_ 100-200 cc/h
  • Once AG corrected than titrate IV insulin to BS
  • When BS lt 13 and AG normal reduce IV insulin gtt
    to 1-2 U/h and add IV glucose if not already done.

9
DKA IV Insulin
  • Can consider switch to SC insulin when
  • AG normalized
  • BS lt 15 mM
  • Insulin IV gtt requirements lt 2U/h
  • Patient able to eat
  • Overlap insulin IV gtt with 1st SC insulin by
    3-4h to avoid recurrent ketosis.

10
DKA Other Rx
  • Bicarbonate
  • May exacerbate hypokalemia
  • Only give if pH lt 6.9 AND evidence of
    cardiovascualr instability (arrythmia, CHF,
    hypotension)
  • 1-2 amps bicarb in 1L D5W IV over 2h until pH gt
    7.1
  • Phosphate
  • Routine IV not recommended
  • Rx symptomatic hypophosphatemia (rhabdo,
    unexplained CHF or respiratory failure, severe
    confusion)
  • 10cc K Phos soln (3.0mEq Pi and 4.4 mEq K/cc) in
    1L NS IV over 8-12h

11
DKA Other Rx
  • Cerebral Edema
  • Usually only kids
  • Persistent decreased LOC despite standard Rx of
    DKA
  • CT scan to confirm diagnosis
  • Decadron 10 mg IV
  • Mannitol 25 mg IV

12
HONC
  • BS gt 55
  • Serum OSM gt 350
  • Coma 25-50
  • Mortality rate 25-70

13
HONC
  • Coma Management
  • ABCs, O2, narcan, D50W, thiamine, etc.
  • IV Fluid Resusciation (10L free water defecit)
  • Insulin
  • IV fluids will decrease BS by 4 mM/L/h by itself
  • For most patients insulin not absolutely
    neccesary
  • Insulin IV bolus 5-10 U, gtt _at_ 1-2 U/h
  • Potassium (replace as in DKA)
  • Identify Rx underlying precipitant

14
BS gt 11.1 mmol/L
Renal threshold for glycosuria (normal GFR)
Decreased WBC function Chemotaxsis Phagocytosis
Decreased Wound Healing
15
Goals of Inpatient DM Management
  • Avoid hypoglycemia and marked hyperglycemia
  • Target BS 7.0 - 11.0 mM
  • Avoid Hypoglycemia
  • Precipitating arrhythmia or other cardiac events
  • Inducing seizure, focal or cognitive defects
    periop
  • Avoid Marked Hyperglycemia (BS gt 11.1 mM)
  • Treat (and avoid) DKA, HONC

16
DM Inpatient Management
  1. Eating
  2. NPO temporary (for a test)
  3. NPO prolonged

17
DM Inpatient Management
  • Eating
  • OHA (T2DM)
  • Insulin (T2DM and T1DM)

18
OHA
Drug BG HbA1c Side-effects
Sulfonylurea FBG 20 1.5-2.0 Hypoglycemia Weight gain
Biguanide FBG 20 1.5-2.0 Lactic acidosis GI intolerance
TZD FBG 2.2-3.6 mM 1.0-1.6 Edema Weight gain
a-glucosidase Inhibitor FPG 14 PPG 25 0.5 GI intolerance
Meglitinide FPG 4 mM PPG 5.6 mM 1.8 Hypoglycemia
19
(No Transcript)
20
Insulin
Type Starts Peaks Duration
Humalog NovoRapid 5-10 min 1-2 hrs 3.5 hrs
Regular 30 min 2-4 hrs 6-8 hrs
NPH Lente 1-2 hrs 6-10 hrs 16-24 hrs
Ultralente 4-6 hrs 8-24 hrs 24-36 hrs
Glargine Immediately None Up to 24 hrs
21
BIDS Therapy
  • T2DM Introduction to insulin
  • Keep on OHAs
  • Start NPH 0.2 U/kg SC qhs
  • Increase by 2-4 U q4d until FBS 4-7
  • If dose gt 30-40U or if BS high late in day
    despite OK FBS than split into 2 injections with
    2/3 acB and 1/3 acD

22
Starting Insulin Regimen
  • TDD 0.5-0.7 U/kg
  • 2/3, 1/3 Regimens
  • 2/3 of TDD acB, 1/3 acD
  • 2/3 of TDD as Long-acting, 1/3 as short acting
  • Pre-mix acB 30/70 acD 30/70
  • MDI Regimens
  • 2/3, 1/3 Regimen move acD long acting to qhs
  • i.e. acB N, H acD H qhs N
  • ac meals H qhs N (bolus 60, basal 40)
  • ac meals H UL q12h (bolus 50, basal 50)

23
Insulin Regimens
  • acB
    acL acD qhs
  • Bedtime NPH (/-bids) N
  • NPH bid N N
  • 30/70 bid 30/70 30/70
  • MDI (3 injections) H N H
    N
  • MDI (gt4 injections) H (/-N) H
    H N
  • MDI (gt4 injections) H UL H
    H UL
  • CSII (Insulin Pump)

24
Guideline for Insulin Adjustments
  • Adjust the insulin that accounts for the high or
    low reading.
  • Always compare an abnormal BS reading with the
    one previous.
  • If insulin dose is
  • Less than 8U, adjust by 1U
  • 8-20U, adjust by 2U
  • gt 20 U, adjust by 10 (increase), 20 (decrease)
  • Dont forget to compensate for a successful
    adjustment

25
acB acL acD qhs Rx
22 (5R) 9 3.1 (O.J.) 15 acB N20 R10 acD R5 qhs N10
20 15 7 8 acB N20 R10 acD R5 qhs N10
22 17 (RN calls) acB N20 R10
Surgeon ? Internal Medicine ? Endocrinologist
?
26
acB acL acD qhs Rx
22 (5R) 9 3.1 (O.J.) 15 acB N20 R10 acD R5 qhs N10
20 15 7 8 acB N20 R10 acD R5 qhs N10
22 17 (RN calls) acB N20 R10
Surgeon Give 5 U Regular SC now Internist Incr
ease qhs N to 12 tonight and acB R to 12
tomorrow Endocrine Increase qhs N to 12 start
tonight Decrease acB N15 R7 starting tomorrow
AM Check 3AM BS tonight
27
Guideline for Insulin Adjustments
  • Adjust the insulin that accounts for the high or
    low reading.
  • Always compare an abnormal BS reading with the
    one previous.
  • If insulin dose is
  • Less than 8U, adjust by 1U
  • 8-20U, adjust by 2U
  • gt 20 U, adjust by 10 (increase), 20 (decrease)
  • Dont forget to compensate for a successful
    adjustment

28
SC Insulin Supplemental Scale
CBG Action
lt 4.0 Call MD
4.1-11.0 nil
11.1-15.0 Humalog 7U SC (0.1U/kg)
15.1-19.9 Humalog 10U SC (0.15 U/kg)
gt 20.0 Call MD
29
DM Inpatient Management
  1. Eating
  2. NPO temporary (for a test)
  3. NPO prolonged

30
NPO for a test T2DM on Diet Rx
  • Schedule test for the AM
  • Hold OHAs on AM of test
  • CBG _at_ 7AM
  • lt 3.0 Consider postpone test
  • 3.1-4.0 IV D5W gtt _at_ 75-100 cc/h
  • 4.1-11.0 Proceed with test, no Rx necessary
  • gt 11.1 IV insulin gtt
  • IV D5W gtt _at_ 75-100 cc/h
  • gt 20.0 Check urine ketones, consider postpone test

31
NPO for a test T1/T2DM on Insulin
  • Schedule the test for the AM
  • Hold AM Insulin on day of test
  • CBG _at_ 7AM
  • lt 3.0 Consider postpone test
  • 3.1-11.0 Give ½ of total AM insulin dose as NPH
    SC
  • IV D5W gtt _at_ 75-100 cc/h
  • gt 11.1 IV insulin gtt
  • IV D5W gtt _at_ 75-100 cc/h
  • gt 20.0 Check urine ketones, consider postpone test

32
DM Inpatient Management
  • Eating
  • NPO temporary (for a test)
  • NPO prolonged
  • Patient put on D5W if not on feeds or TPN
  • IV insulin gtt
  • SC NPH or UL q12h (/- supplemental scale)

33
Insulin IV gtt
  • Add 50 U of Human regular insulin (Humulin R or
    Novolin Toronto) to 500cc D5W (1U/10cc).
  • Flush discard first 50cc.
  • Infuse insulin solution by IVAC (intravenous
    infusion pump), piggybacked into D5W running at
    100cc/h.
  • Start insulin _at_ 0.9 U/h (9cc/h) or start at a
    rate dependent on patients insulin dose
  • IV insulin gtt rate ( ½ TDD ) / 24

34
Insulin IV gtt
  • CPG q1h x 2, then q2h (if BS stable x 2-3
    readings consider q4h)
  • Adjust Insulin IV infusion rate as per scale
    below
  • lt4.0 Call MD
  • 4.1-5.0 0.7 U/h ( 7cc/h)
  • 5.1-6.0 0.9 U/h ( 9cc/h)
  • 6.1-7.0 1.2 U/h (12cc/h)
  • 7.1-9.0 1.5 U/h (15cc/h)
  • 9.1-11.0 2.0 U/h (20cc/h)
  • 11.1-13.0 2.5 U/h (25cc/h)
  • 13.1-15.0 3.0 U/h (30cc/h)
  • 15.1-17.0 3.5 U/h (35cc/h)
  • 17.1-20.0 4.0 U/h (40cc/h)
  • gt20.1 Call MD

35
Evidence to support Inpatient BS control?
  • DIGAMI
  • AMI, prior dx DM or BS gt 11 mM
  • IV insulin gtt started _at_ 5 U/h
  • Titrated to keep BS 7-10.9 mM
  • Insulin IV gt 24h ? MDI gt 3 months
  • No in-hospital mortality benefit.
  • Rx Increased hospitalization by 1.8d
  • 0.5 reduction HbA1c _at_ 3 months
  • _at_ 1 year on Insulin 72 Rx Group 49 Cntrl
    Group
  • 1 year mort ARR 7.5 NNT 13
  • 3.4 y mort ARR 11 NNT 9

36
Evidence to support Inpatient BS control?
  • Leuven, Belgium Study
  • ICU patients (63 CV Sx)
  • If BS gt 6.1 mM Rx with IV insulin gtt TPN /-
    tube feeds
  • Start IV insulin _at_ 2-4 U/h, titrated to BS
    4.4-6.1 mM
  • Ave insulin dose Rx group 3.0 U/h Cntrl
    group 1.4 U/h
  • Once out of ICU relaxed treatment goal to lt 11.1
    mM
  • Mortality in ICU ARR 3.4 NNT 29
  • Mortality in-hospital ARR 3.7 NNT 27
  • Greatest reduction in mortality was
    sepsis-related.
  • Insulin Rx reduced bacteremia, ARF needing HD,
    need for PRBC, critical illness polyneuropathy,
    duration of ventilation and length of stay in ICU
  • To what extent were benefits nutrition related as
    opposed to insulin related?
Write a Comment
User Comments (0)
About PowerShow.com